Johnson & Johnson (NYSE:JNJ) Shares Sold by Veery Capital LLC

Veery Capital LLC cut its holdings in Johnson & Johnson (NYSE:JNJ) by 43.9% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,235 shares of the company’s stock after selling 967 shares during the quarter. Veery Capital LLC’s holdings in Johnson & Johnson were worth $200,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. Seizert Capital Partners LLC increased its holdings in shares of Johnson & Johnson by 1.0% in the third quarter. Seizert Capital Partners LLC now owns 244,057 shares of the company’s stock valued at $39,552,000 after purchasing an additional 2,441 shares during the period. Kinsale Capital Group Inc. grew its position in Johnson & Johnson by 16.8% in the 3rd quarter. Kinsale Capital Group Inc. now owns 44,251 shares of the company’s stock valued at $7,171,000 after buying an additional 6,381 shares during the last quarter. River Street Advisors LLC increased its stake in Johnson & Johnson by 0.6% in the 3rd quarter. River Street Advisors LLC now owns 12,667 shares of the company’s stock valued at $2,053,000 after buying an additional 75 shares during the period. Turtle Creek Wealth Advisors LLC raised its position in Johnson & Johnson by 7.1% during the 3rd quarter. Turtle Creek Wealth Advisors LLC now owns 5,588 shares of the company’s stock worth $906,000 after buying an additional 372 shares during the last quarter. Finally, Evergreen Wealth Management LLC boosted its holdings in shares of Johnson & Johnson by 142.1% in the third quarter. Evergreen Wealth Management LLC now owns 24,617 shares of the company’s stock valued at $3,990,000 after acquiring an additional 14,450 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the sale, the vice president now owns 18,973 shares in the company, valued at $3,131,683.38. The trade was a 22.90 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on JNJ. Daiwa Capital Markets downgraded shares of Johnson & Johnson from an “outperform” rating to a “neutral” rating and reduced their price objective for the company from $160.00 to $150.00 in a research report on Tuesday, July 23rd. Royal Bank of Canada lifted their price target on Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a research note on Wednesday, October 16th. Daiwa America lowered Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 23rd. Wells Fargo & Company raised their target price on Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a report on Wednesday, October 16th. Finally, StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 14th. Seven investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average target price of $175.94.

Johnson & Johnson Stock Up 1.4 %

JNJ opened at $154.00 on Friday. The business’s fifty day simple moving average is $161.35 and its 200 day simple moving average is $156.10. Johnson & Johnson has a 52 week low of $143.13 and a 52 week high of $168.85. The firm has a market cap of $370.77 billion, a P/E ratio of 22.29, a PEG ratio of 2.74 and a beta of 0.53. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. The business had revenue of $22.47 billion during the quarter, compared to the consensus estimate of $22.17 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The company’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.66 earnings per share. As a group, equities research analysts anticipate that Johnson & Johnson will post 9.93 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be issued a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 3.22%. The ex-dividend date of this dividend is Tuesday, November 26th. Johnson & Johnson’s dividend payout ratio (DPR) is 71.78%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.